Provention Bio | Investor Relations

Investor Alerts

Jun 30, 2020

Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual...
Jun 29, 2020

Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has been added to the broad-market...
Jun 22, 2020

Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public...
Jun 17, 2020

Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced...
Jun 16, 2020

Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public...
Jun 15, 2020

Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients

-One Course of Teplizumab Now Shown to Delay Insulin-Dependent T1D by a Median of Approximately Three Years Compared to Placebo-

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended follow-up data showing a single 14-day...
May 28, 2020

Provention Bio to Present at the Jefferies Virtual Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies...
May 20, 2020

Provention Bio Announces Changes to its Board of Directors

- Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced two changes to its board of...
May 18, 2020

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine

-- The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish...
May 7, 2020

Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results and provided a...
Apr 30, 2020

Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first...
Apr 16, 2020

Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

- Rolling BLA Submission Initiated Under Breakthrough Therapy Designation

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the initiation of the rolling...
Mar 16, 2020

Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes

- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced a temporary pause in the...
Mar 12, 2020

Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

- Expect to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
Mar 12, 2020

Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279

-PRV-3279 Inhibited the Function of B Cells, Durably and Without Depletion-

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced positive top-line results from...
Mar 5, 2020

Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth...
Feb 19, 2020

Provention Bio to Present at Upcoming Conferences

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
Feb 6, 2020

Provention Bio Highlights Critical New Research Studies on Type One Diabetes

JDRF T1D Fund Study Estimates 2.3 Million People at Risk Globally to Develop Stage 3 T1D, Which Already Affects 18 Million People Globally

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new research studies on...
Jan 8, 2020

Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jason Hoitt as...
Dec 12, 2019

Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA

Expects to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B...
Nov 5, 2019

Provention Bio Reports Third Quarter 2019 Financial Results

- PRV-031 (teplizumab) Granted Breakthrough Therapy and PRIME Designations -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third...
Oct 29, 2019

Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third...
Oct 24, 2019

Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the European Medicines Agency...
Oct 22, 2019

Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

-Study Did Not Achieve Primary Endpoint Due to High Placebo Effect-

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced top-line results from its...
Sep 26, 2019

Sean Doherty Joins Provention Bio Board of Directors

- T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sean Doherty...

Show per page

news releases